The death toll from Lassa fever in Nigeria has risen to 53 according to the latest situation report of the disease obtained ...

The World Health Organisation has defined Lassa fever as an acute viral haemorrhagic illness caused by the Lassa virus, a member of the arenavirus family of viruses. Humans usually become ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing next generation immunotherapeutics based on its proprietary arenavirus platform. The company ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...

In a challenging year for biotech firms, Hookipa Pharma Inc (NASDAQ:HOOK). shares have tumbled to a 52-week low, touching down at $1.71. According to InvestingPro analysis, the company, known for its ...

The Nigeria Centre for Disease Control and Prevention has confirmed 143 cases of Lassa fever out of the 484 suspected cases from December 30, 2024, to January 12, 2025, in seven states across 32 local ...

Hookipa Pharma (Hookipa) is a clinical-stage biopharmaceutical company that develops novel immunotherapies through its arenavirus platform for cancer and chronic infectious diseases using its ...

HOOKIPA Pharma Inc. has announced the completion of participant enrollment in a Phase 1b clinical trial for HB-500, a next-generation therapeutic vaccine aimed at treating HIV. The trial ...